StockClub

EGRX

EGRXEagle Pharmaceuticals, Inc.$ --
Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc.

EGRX

$ -

-

Review earnings summary, surprise history, and upcoming forecasts.

wallet
Earnings Summary
Updated: 06/30/2023FY2023 Q2
Revenue
65M USD
YoY -12.8%
Operating Income
10M USD
YoY +367.7%
Net Income
5M USD
YoY +154.6%
EPS
0.39$
YoY +152.7%

Revenue

$131M
FY2021 Q3$129.2M
$129.2M
Q3
FY2021 Q4$171.5M
$171.5M
Q4
FY2022 Q1$115.9M
$115.9M
Q1
FY2022 Q2$190M
$190M
Q2
FY2022 Q3$255.9M
$255.9M
Q3
FY2022 Q4$316.6M
$316.6M
Q4
FY2023 Q1$66.3M
$66.3M
Q1
FY2023 Q2$131M
$131M
Q2
Actual
$-59.1M (-31.1%)

Net Income

$10.9M
FY2021 Q3$-2.4M
$-2.4M
Q3
FY2021 Q4$-8.6M
$-8.6M
Q4
FY2022 Q1$44.1M
$44.1M
Q1
FY2022 Q2$34.6M
$34.6M
Q2
FY2022 Q3$31.1M
$31.1M
Q3
FY2022 Q4$39.3M
$39.3M
Q4
FY2023 Q1$5.8M
$5.8M
Q1
FY2023 Q2$10.9M
$10.9M
Q2
Actual
$-23.7M (-68.5%)

Surprise History

Actual RevenueAnalyst Estimate
FY2017
Actual:$236.7M
FY2017
$236.7M
FY2018
Actual:$213.3M
FY2018
$213.3M
FY2019
Actual:$195.9M
FY2019
$195.9M
FY2020
Actual:$187.8M
FY2020
$187.8M
FY2021
Actual:$171.5M
FY2021
$171.5M
FY2022
Actual:$316.6M
FY2022
$316.6M

Analyst Estimates

No forecast data